The Phase IIb trial missed its primary endpoint in patients with treatment-resistant depression.
- First-in-human data for gene therapy signals potential in childhood blindness February 21, 2025
- Stabilising Europe’s generic medicine supply February 20, 2025
- Photochemistry development aids peptide-based therapy progress February 19, 2025
- Innovative nanoparticle-based technique could advance pharmaceutical formulations February 18, 2025
- Water-based reactors offer pharmaceutical industry a safer alternative to toxic solvents February 17, 2025
- Pharmaceutical training boost: how the growth and skills levy could shape industry development February 17, 2025
- FDA Approves First Rapid-Acting Insulin Biosimilar Product for the Treatment of Diabetes February 19, 2025
- IP Litigator Publishes Goodwin Partners’ BPCIA Research February 18, 2025
- UK’s MHRA Grants Marketing Authorization for Chikungunya Vaccine February 17, 2025
- Regulatory Updates on Samsung’s Denosumab Biosimilars February 17, 2025
- Dr. Reddy’s Secures License from Henlius to Market Daratumumab Biosimilar in the U.S. and Europe February 14, 2025
- From Data Gaps to Revenue Gains: Harnessing the Power of Comprehensive Data to Drive GTN February 21, 2025
- Vanishing Act: Why Small Pharmacies Exited Medicare Part D Networks for 2025 February 18, 2025
- Compliance is Futile Without Transparency: 340B, MDRP, MFP Overlap Lead to Iceberg Ahead February 14, 2025
- Why Plan Sponsors and PBMs Are Still Falling Hard for Copay Maximizers February 12, 2025
- Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner February 7, 2025
- Vertical Integration Redux: How Pharmaceutical Wholesalers Are Transforming the Buy-and-Bill Market (Video) February 4, 2025
- Informa Connect's Access USA February 3, 2025